TY - JOUR
T1 - Therapeutic management of atopic eczema
AU - Traidl-Hoffmann, Claudia
AU - Mempel, Martin
AU - Belloni, Benedetta
AU - Ring, Johannes
AU - Schnopp, Christina
PY - 2010/3
Y1 - 2010/3
N2 - The present review aims at giving a condensed view on the current status of therapy of atopic eczema - a common chronically relapsing inflammatory skin disease. Atopic eczema is a multifactorial disease with a tendency for chronification. Owing to the associated genetic factors, therapeutic amelioration of skin symptoms is often only transient. Therefore, treatment basically focuses on symptomatic relief. Atopic eczema treatment should more than any other disease be guided by an individualized approach taking not only the phenotype and genotype of the disease but also psychosocial and gender aspects into account. Significant gains have been made in our understanding of atopic eczema, especially recent insights into genetic and immunologic mechanisms, but still, there is no single treatment to date that has proven to be the quantum leap for atopic patients. Novel treatments have been developed and trialled, however, more studies on novel therapies such as biologicals addressing efficacy, optimum dose and duration of treatment and the target phenotype are urgently needed. Hopefully, the tremendous progress in basic research in the last years will provide new targets for prevention and treatment in the future.
AB - The present review aims at giving a condensed view on the current status of therapy of atopic eczema - a common chronically relapsing inflammatory skin disease. Atopic eczema is a multifactorial disease with a tendency for chronification. Owing to the associated genetic factors, therapeutic amelioration of skin symptoms is often only transient. Therefore, treatment basically focuses on symptomatic relief. Atopic eczema treatment should more than any other disease be guided by an individualized approach taking not only the phenotype and genotype of the disease but also psychosocial and gender aspects into account. Significant gains have been made in our understanding of atopic eczema, especially recent insights into genetic and immunologic mechanisms, but still, there is no single treatment to date that has proven to be the quantum leap for atopic patients. Novel treatments have been developed and trialled, however, more studies on novel therapies such as biologicals addressing efficacy, optimum dose and duration of treatment and the target phenotype are urgently needed. Hopefully, the tremendous progress in basic research in the last years will provide new targets for prevention and treatment in the future.
KW - Atopic eczema
KW - Pernonalized therapy
UR - http://www.scopus.com/inward/record.url?scp=77951736238&partnerID=8YFLogxK
U2 - 10.2174/138920010791196319
DO - 10.2174/138920010791196319
M3 - Review article
C2 - 20406188
AN - SCOPUS:77951736238
SN - 1389-2002
VL - 11
SP - 234
EP - 241
JO - Current Drug Metabolism
JF - Current Drug Metabolism
IS - 3
ER -